![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: > Pardi Darrell S.
Publisher: Adis International
ISSN: 1170-229X
Source: Drugs & Aging, Vol.27, Iss.8, 2010-08, pp. : 617-624
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Treatment of Inflammatory Bowel Disease in the Elderly: An Update
By Pardi D.S. Loftus Jr E.V. Camilleri M.
Drugs & Aging, Vol. 19, Iss. 5, 2002-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Macrophages in Inflammatory Bowel Disease
Current Drug Targets. Inflammation & Allergy, Vol. 2, Iss. 2, 2003-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Mesalazine for the treatment of inflammatory bowel disease
Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Costs of Inflammatory Bowel Disease in Germany
By Stark Renee
PharmacoEconomics, Vol. 24, Iss. 8, 2006-01 ,pp. :